Shanghai Kaibao Pharmaceutical - Asset Resilience Ratio
Shanghai Kaibao Pharmaceutical (300039) has an Asset Resilience Ratio of 5.01% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Shanghai Kaibao Pharmaceutical (300039) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Shanghai Kaibao Pharmaceutical's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300039 current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Kaibao Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Shanghai Kaibao Pharmaceutical to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥229.99 Million | 5.01% |
| Total Liquid Assets | CN¥229.99 Million | 5.01% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Kaibao Pharmaceutical maintains only 5.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Kaibao Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Shanghai Kaibao Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Shanghai Kaibao Pharmaceutical (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Kaibao Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 1.22% | CN¥58.53 Million ≈ $8.57 Million |
CN¥4.78 Billion ≈ $699.22 Million |
-2.76pp |
| 2024-12-31 | 3.98% | CN¥180.02 Million ≈ $26.34 Million |
CN¥4.52 Billion ≈ $661.19 Million |
+0.71pp |
| 2023-12-31 | 3.28% | CN¥150.01 Million ≈ $21.95 Million |
CN¥4.58 Billion ≈ $670.15 Million |
+0.08pp |
| 2022-12-31 | 3.19% | CN¥136.07 Million ≈ $19.91 Million |
CN¥4.26 Billion ≈ $623.27 Million |
+1.67pp |
| 2021-12-31 | 1.53% | CN¥51.26 Million ≈ $7.50 Million |
CN¥3.36 Billion ≈ $491.06 Million |
-2.46pp |
| 2020-12-31 | 3.98% | CN¥114.65 Million ≈ $16.78 Million |
CN¥2.88 Billion ≈ $421.04 Million |
-13.10pp |
| 2019-12-31 | 17.08% | CN¥485.57 Million ≈ $71.05 Million |
CN¥2.84 Billion ≈ $415.95 Million |
+14.01pp |
| 2018-12-31 | 3.07% | CN¥84.28 Million ≈ $12.33 Million |
CN¥2.75 Billion ≈ $402.03 Million |
-0.79pp |
| 2017-12-31 | 3.86% | CN¥103.38 Million ≈ $15.13 Million |
CN¥2.68 Billion ≈ $392.13 Million |
+2.21pp |
| 2016-12-31 | 1.64% | CN¥41.58 Million ≈ $6.08 Million |
CN¥2.53 Billion ≈ $369.91 Million |
+0.67pp |
| 2015-12-31 | 0.98% | CN¥23.72 Million ≈ $3.47 Million |
CN¥2.43 Billion ≈ $355.10 Million |
-8.00pp |
| 2014-12-31 | 8.97% | CN¥190.00 Million ≈ $27.80 Million |
CN¥2.12 Billion ≈ $309.84 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more